Cargando…
The predictive value of 53BP1 and BRCA1 mRNA expression in advanced non-small-cell lung cancer patients treated with first-line platinum-based chemotherapy
Platinum-based chemotherapy is the standard first-line treatment for non-oncogene-addicted non-small cell lung cancers (NSCLCs) and the analysis of multiple DNA repair genes could improve current models for predicting chemosensitivity. We investigated the potential predictive role of components of t...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3858546/ https://www.ncbi.nlm.nih.gov/pubmed/24197907 |
_version_ | 1782295288026759168 |
---|---|
author | Bonanno, Laura Costa, Carlota Majem, Margarita Sanchez, Jose Javier Gimenez-Capitan, Ana Rodriguez, Ignacio Vergenegre, Alain Massuti, Bartomeu Favaretto, Adolfo Rugge, Massimo Pallares, Cinta Taron, Miquel Rosell, Rafael |
author_facet | Bonanno, Laura Costa, Carlota Majem, Margarita Sanchez, Jose Javier Gimenez-Capitan, Ana Rodriguez, Ignacio Vergenegre, Alain Massuti, Bartomeu Favaretto, Adolfo Rugge, Massimo Pallares, Cinta Taron, Miquel Rosell, Rafael |
author_sort | Bonanno, Laura |
collection | PubMed |
description | Platinum-based chemotherapy is the standard first-line treatment for non-oncogene-addicted non-small cell lung cancers (NSCLCs) and the analysis of multiple DNA repair genes could improve current models for predicting chemosensitivity. We investigated the potential predictive role of components of the 53BP1 pathway in conjunction with BRCA1. The mRNA expression of BRCA1, MDC1, CASPASE3, UBC13, RNF8, 53BP1, PIAS4, UBC9 and MMSET was analyzed by real-time PCR in 115 advanced NSCLC patients treated with first-line platinum-based chemotherapy. Patients expressing low levels of both BRCA1 and 53BP1 obtained a median progression-free survival of 10.3 months and overall survival of 19.3 months, while among those with low BRCA1 and high 53BP1 progression-free survival was 5.9 months (P <0.0001) and overall survival was 8.2 months (P=0.001). The expression of 53BP1 refines BRCA1-based predictive modeling to identify patients most likely to benefit from platinum-based chemotherapy. |
format | Online Article Text |
id | pubmed-3858546 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-38585462013-12-11 The predictive value of 53BP1 and BRCA1 mRNA expression in advanced non-small-cell lung cancer patients treated with first-line platinum-based chemotherapy Bonanno, Laura Costa, Carlota Majem, Margarita Sanchez, Jose Javier Gimenez-Capitan, Ana Rodriguez, Ignacio Vergenegre, Alain Massuti, Bartomeu Favaretto, Adolfo Rugge, Massimo Pallares, Cinta Taron, Miquel Rosell, Rafael Oncotarget Research Paper Platinum-based chemotherapy is the standard first-line treatment for non-oncogene-addicted non-small cell lung cancers (NSCLCs) and the analysis of multiple DNA repair genes could improve current models for predicting chemosensitivity. We investigated the potential predictive role of components of the 53BP1 pathway in conjunction with BRCA1. The mRNA expression of BRCA1, MDC1, CASPASE3, UBC13, RNF8, 53BP1, PIAS4, UBC9 and MMSET was analyzed by real-time PCR in 115 advanced NSCLC patients treated with first-line platinum-based chemotherapy. Patients expressing low levels of both BRCA1 and 53BP1 obtained a median progression-free survival of 10.3 months and overall survival of 19.3 months, while among those with low BRCA1 and high 53BP1 progression-free survival was 5.9 months (P <0.0001) and overall survival was 8.2 months (P=0.001). The expression of 53BP1 refines BRCA1-based predictive modeling to identify patients most likely to benefit from platinum-based chemotherapy. Impact Journals LLC 2013-07-31 /pmc/articles/PMC3858546/ /pubmed/24197907 Text en Copyright: © 2013 Bonanno et al. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited |
spellingShingle | Research Paper Bonanno, Laura Costa, Carlota Majem, Margarita Sanchez, Jose Javier Gimenez-Capitan, Ana Rodriguez, Ignacio Vergenegre, Alain Massuti, Bartomeu Favaretto, Adolfo Rugge, Massimo Pallares, Cinta Taron, Miquel Rosell, Rafael The predictive value of 53BP1 and BRCA1 mRNA expression in advanced non-small-cell lung cancer patients treated with first-line platinum-based chemotherapy |
title | The predictive value of 53BP1 and BRCA1 mRNA expression in advanced non-small-cell lung cancer patients treated with first-line platinum-based chemotherapy |
title_full | The predictive value of 53BP1 and BRCA1 mRNA expression in advanced non-small-cell lung cancer patients treated with first-line platinum-based chemotherapy |
title_fullStr | The predictive value of 53BP1 and BRCA1 mRNA expression in advanced non-small-cell lung cancer patients treated with first-line platinum-based chemotherapy |
title_full_unstemmed | The predictive value of 53BP1 and BRCA1 mRNA expression in advanced non-small-cell lung cancer patients treated with first-line platinum-based chemotherapy |
title_short | The predictive value of 53BP1 and BRCA1 mRNA expression in advanced non-small-cell lung cancer patients treated with first-line platinum-based chemotherapy |
title_sort | predictive value of 53bp1 and brca1 mrna expression in advanced non-small-cell lung cancer patients treated with first-line platinum-based chemotherapy |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3858546/ https://www.ncbi.nlm.nih.gov/pubmed/24197907 |
work_keys_str_mv | AT bonannolaura thepredictivevalueof53bp1andbrca1mrnaexpressioninadvancednonsmallcelllungcancerpatientstreatedwithfirstlineplatinumbasedchemotherapy AT costacarlota thepredictivevalueof53bp1andbrca1mrnaexpressioninadvancednonsmallcelllungcancerpatientstreatedwithfirstlineplatinumbasedchemotherapy AT majemmargarita thepredictivevalueof53bp1andbrca1mrnaexpressioninadvancednonsmallcelllungcancerpatientstreatedwithfirstlineplatinumbasedchemotherapy AT sanchezjosejavier thepredictivevalueof53bp1andbrca1mrnaexpressioninadvancednonsmallcelllungcancerpatientstreatedwithfirstlineplatinumbasedchemotherapy AT gimenezcapitanana thepredictivevalueof53bp1andbrca1mrnaexpressioninadvancednonsmallcelllungcancerpatientstreatedwithfirstlineplatinumbasedchemotherapy AT rodriguezignacio thepredictivevalueof53bp1andbrca1mrnaexpressioninadvancednonsmallcelllungcancerpatientstreatedwithfirstlineplatinumbasedchemotherapy AT vergenegrealain thepredictivevalueof53bp1andbrca1mrnaexpressioninadvancednonsmallcelllungcancerpatientstreatedwithfirstlineplatinumbasedchemotherapy AT massutibartomeu thepredictivevalueof53bp1andbrca1mrnaexpressioninadvancednonsmallcelllungcancerpatientstreatedwithfirstlineplatinumbasedchemotherapy AT favarettoadolfo thepredictivevalueof53bp1andbrca1mrnaexpressioninadvancednonsmallcelllungcancerpatientstreatedwithfirstlineplatinumbasedchemotherapy AT ruggemassimo thepredictivevalueof53bp1andbrca1mrnaexpressioninadvancednonsmallcelllungcancerpatientstreatedwithfirstlineplatinumbasedchemotherapy AT pallarescinta thepredictivevalueof53bp1andbrca1mrnaexpressioninadvancednonsmallcelllungcancerpatientstreatedwithfirstlineplatinumbasedchemotherapy AT taronmiquel thepredictivevalueof53bp1andbrca1mrnaexpressioninadvancednonsmallcelllungcancerpatientstreatedwithfirstlineplatinumbasedchemotherapy AT rosellrafael thepredictivevalueof53bp1andbrca1mrnaexpressioninadvancednonsmallcelllungcancerpatientstreatedwithfirstlineplatinumbasedchemotherapy AT bonannolaura predictivevalueof53bp1andbrca1mrnaexpressioninadvancednonsmallcelllungcancerpatientstreatedwithfirstlineplatinumbasedchemotherapy AT costacarlota predictivevalueof53bp1andbrca1mrnaexpressioninadvancednonsmallcelllungcancerpatientstreatedwithfirstlineplatinumbasedchemotherapy AT majemmargarita predictivevalueof53bp1andbrca1mrnaexpressioninadvancednonsmallcelllungcancerpatientstreatedwithfirstlineplatinumbasedchemotherapy AT sanchezjosejavier predictivevalueof53bp1andbrca1mrnaexpressioninadvancednonsmallcelllungcancerpatientstreatedwithfirstlineplatinumbasedchemotherapy AT gimenezcapitanana predictivevalueof53bp1andbrca1mrnaexpressioninadvancednonsmallcelllungcancerpatientstreatedwithfirstlineplatinumbasedchemotherapy AT rodriguezignacio predictivevalueof53bp1andbrca1mrnaexpressioninadvancednonsmallcelllungcancerpatientstreatedwithfirstlineplatinumbasedchemotherapy AT vergenegrealain predictivevalueof53bp1andbrca1mrnaexpressioninadvancednonsmallcelllungcancerpatientstreatedwithfirstlineplatinumbasedchemotherapy AT massutibartomeu predictivevalueof53bp1andbrca1mrnaexpressioninadvancednonsmallcelllungcancerpatientstreatedwithfirstlineplatinumbasedchemotherapy AT favarettoadolfo predictivevalueof53bp1andbrca1mrnaexpressioninadvancednonsmallcelllungcancerpatientstreatedwithfirstlineplatinumbasedchemotherapy AT ruggemassimo predictivevalueof53bp1andbrca1mrnaexpressioninadvancednonsmallcelllungcancerpatientstreatedwithfirstlineplatinumbasedchemotherapy AT pallarescinta predictivevalueof53bp1andbrca1mrnaexpressioninadvancednonsmallcelllungcancerpatientstreatedwithfirstlineplatinumbasedchemotherapy AT taronmiquel predictivevalueof53bp1andbrca1mrnaexpressioninadvancednonsmallcelllungcancerpatientstreatedwithfirstlineplatinumbasedchemotherapy AT rosellrafael predictivevalueof53bp1andbrca1mrnaexpressioninadvancednonsmallcelllungcancerpatientstreatedwithfirstlineplatinumbasedchemotherapy |